المؤلفون: Kiyoshi Minohara, Shinichiro Maseki, Nobukazu Tanaka, Shinichi Esaki, Akihiro Murashima, Shinya Ozaki, Taijiro Ozawa, Kazuhiro Nakai, Keisuke Oguri, Ayano Matsumura, Kazuho Moribe, Sae Imaizumi, Takuma Matoba, Gaku Takano, Sho Iwaki, Shinichi Iwasaki, Shoji Mitsuya, Wataru Hojo, Daisuke Kawakita, Hiroshi Tsuge, Ikuma Harata

المصدر: Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Scientific Reports

مصطلحات موضوعية: Oncology, Adult, Male, medicine.medical_specialty, Science, MEDLINE, Kaplan-Meier Estimate, Article, Prognostic score, Prognostic markers, Text mining, Internal medicine, medicine, Chemotherapy, Humans, Neoplasm Metastasis, Adverse effect, Head and neck cancer, Cancer, Aged, Multidisciplinary, Performance status, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Prognosis, Progression-Free Survival, Nivolumab, Treatment Outcome, Head and Neck Neoplasms, Medicine, Female, Immunotherapy, Neoplasm Recurrence, Local, business

الوصف: Although several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological factors on survival in RM-HNC patients treated with nivolumab. We reviewed 126 RM-HNC patients from seven institutes. We evaluated the prognostic effects of clinico-hematological factors on survival. The median overall survival (OS) was 12.3 months, and the 1 year-OS rate was 51.2%. Patients without immune-related adverse events, lower relative eosinophil count, worse best overall response, higher performance status, and higher modified Glasgow Prognostic Score had worse survival. The score, generated by combining these factors, was associated with survival. Patients with score of 4–5 had worse survival than those with score of 2–3 and 0–1 [adjusted HR for PFS: score of 4–5, 7.77 (3.98–15.15); score of 2–3, 3.44 (1.95–6.06), compared to score of 0–1], [adjusted HR for OS: score of 4–5, 14.66 (4.28–50.22); score of 2–3, 7.63 (2.29–25.37), compared to score of 0–1]. Our novel prognostic score utilizing clinico-hematological factors might be useful to establish an individual treatment strategy in RM-HNC patients treated with nivolumab therapy.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b11aa56338b04e66f1a7f3d47255416cTest
https://doaj.org/article/83aafb03d05a4f159e72936107a43a7eTest

المؤلفون: Effie Ho, Paul Okunieff, Hui Xu, Michael Y. Sha, Jianwei Lu, Chenchen Li, Xiaorong Zhou, Ping Ding, Daniel Y. Li, Aiguo Zhang, Zhao Zhang, Haiyan Meng, Ronglei Li, Jinwei Du

المصدر: Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports

مصطلحات موضوعية: Male, Oncology, Lung Neoplasms, medicine.medical_treatment, Biomarkers, Pharmacological, Prognostic markers, Plasma, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Multidisciplinary, Middle Aged, Prognosis, Progression-Free Survival, Tumor Burden, Plasma.cfDNA, medicine.anatomical_structure, Cohort, Carcinoma, Squamous Cell, Adenocarcinoma, Medicine, Female, Cell-Free Nucleic Acids, medicine.drug, Adult, medicine.medical_specialty, Bevacizumab, Science, Predictive markers, Antibodies, Monoclonal, Humanized, Article, Disease-Free Survival, Internal medicine, Biomarkers, Tumor, medicine, Carcinoma, Humans, Liquid biopsy, Lung cancer, Protein Kinase Inhibitors, Aged, Retrospective Studies, Chemotherapy, Lung, business.industry, Cancer, medicine.disease, Kinetics, Regimen, business, Non-small-cell lung cancer

الوصف: Background: Tyrosine Kinases Inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs, bevacizumab) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancer including non-small-cell lung cancer (NSCLC). Cell-free DNA (cfDNA) has been adapted as a convenient liquid biopsy that reflects characteristics of the status of both the primary and metastatic tumors, assisting in personalized medicine. This study aims to evaluate the utility of cfDNA as a prognostic biomarker and efficacy predictor of chemotherapy with or without these precision therapies in NSCLC patients. Methods: Peripheral cfDNA levels were quantified in 154 patients with NSCLC before (baseline) and after (post-chemotherapy) the first target cycle of chemotherapy. These patients were divided into four subgroups receiving chemotherapy only, chemotherapy plus TKIs, chemotherapy plus VEGFIs, and chemotherapy plus immune checkpoint inhibitors (ICIs), respectively. The correlations of cfDNA with tumor burden, clinical characteristics, progression-free survival (PFS), objective response ratio (ORR), and therapy regimens were analyzed. Results: Baseline cfDNA, but not post-chemotherapy, positively correlates with tumor burden. cfDNA Ratio (post-chemotherapy/baseline) well distinguished responsive individuals (CR/PR) from non-responsive patients (PD/SD). Additionally, cfDNA Ratio was found to be negatively correlated with PFS in lung adenocarcinoma (LUAD), but not in lung squamous-cell carcinoma (LUSC). LUAD patients with low cfDNA Ratio benefit significantly including prolonged PFS and improved ORR, compared with those with high cfDNA Ratio. When stratified by therapy regimen, the predictive value of cfDNA Ratio is significant in patients with chemotherapy plus VEGFIs. Conclusion: The kinetics of plasma cfDNA during the chemotherapy may function as a prognostic biomarker and efficacy predictor for NSCLC patients. Funding Statement: None Declaration of Interests: None. Ethics Approval Statement: All participants signed the informed consent agreement. The study was approved by the clinical research ethics committee of the Jiangsu Cancer Hospital and was conducted following the Declaration of Helsinki.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1d0523e97cdd57bb61ad5efaf79cb56Test
https://doaj.org/article/b2343cf2b10446a4ab9c404bea005c66Test

المؤلفون: Yuval Mizrakli, Amos Douvdevani, Maia Rosenthal, Victor Novack, Samuel Ariad, Ravit Agassi, Reut Riff, Shaked Yarza, David Czeiger, Irena Lazarev, Michal Peled

المصدر: Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports

مصطلحات موضوعية: 0301 basic medicine, Oncology, Receptor, ErbB-2, medicine.medical_treatment, lcsh:Medicine, Circulating Tumor DNA, Prognostic markers, Breast cancer, 0302 clinical medicine, Medicine, Prospective Studies, Prospective cohort study, lcsh:Science, Aged, 80 and over, Multidisciplinary, medicine.diagnostic_test, Middle Aged, Prognosis, Combined Modality Therapy, Tumor Burden, Receptors, Estrogen, Cell-free fetal DNA, Female, Receptors, Progesterone, Cell-Free Nucleic Acids, Mammography, Adult, medicine.medical_specialty, Adolescent, Breast Neoplasms, Article, Young Adult, 03 medical and health sciences, Internal medicine, Biopsy, Biomarkers, Tumor, Humans, In patient, Aged, Chemotherapy, business.industry, lcsh:R, Cancer, medicine.disease, 030104 developmental biology, lcsh:Q, business, Biomarkers, 030217 neurology & neurosurgery, Follow-Up Studies

الوصف: Mammography has a crucial role in the detection of breast cancer (BC), yet it is not limitation-free. We hypothesized that the combination of mammography and cell-free DNA (cfDNA) levels may better discriminate patients with cancer. This prospective study included 259 participants suspected with BC before biopsy. Blood samples were taken before biopsy and from some patients during and at the end of treatment. cfDNA blood levels were measured using our simple fluorescent assay. The primary outcome was the pathologic diagnosis of BC, and the secondary aims were to correlate cfDNA to severity, response to treatments, and outcome. Median cfDNA blood levels were similar in patients with positive and negative biopsy: 577 vs. 564 ng/ml (p = 0.98). A significant decrease in cfDNA blood level was noted after the following treatments: surgery, surgery and radiation, neo-adjuvant chemotherapy and surgery, and at the end of all treatments. To conclude, the cfDNA level could not be used in suspected patients to discriminate BC. Reduction of tumor burden by surgery and chemotherapy is associated with reduction of cfDNA levels. In a minority of patients, an increase in post-treatment cfDNA blood level may indicate the presence of a residual tumor and higher risk. Further outcome assessment for a longer period is suggested.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fce98dab5f360391c56b453fbff8e82Test
http://link.springer.com/article/10.1038/s41598-020-71357-4Test

المؤلفون: Sophie Giraud, Noemie Lang, Solene De Talhouet, Adrien Buisson, Valeria Viassolo, S. Intidhar Labidi-Galy, Valérie Bonadona, Alexandre Bodmer, Aurélie Ayme, Alex Friedlaender, Jean-Christophe Tille, Aurelie Vuilleumier, Christine Lasset, Pierre O. Chappuis, Olivier Tredan, Isabelle Treilleux, Julien Péron

المصدر: Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Scientific Reports, Vol. 10, No 1 (2020) P. 7073

مصطلحات موضوعية: 0301 basic medicine, Oncology, endocrine system diseases, Adjuvant chemotherapy, lcsh:Medicine, Triple Negative Breast Neoplasms, ddc:616.07, Triple Negative Breast Neoplasms/genetics/mortality/therapy, Prognostic markers, Breast cancer, 0302 clinical medicine, skin and connective tissue diseases, lcsh:Science, Cancer genetics, Adjuvant, ddc:616, Multidisciplinary, BRCA1 Protein, Hazard ratio, Middle Aged, BRCA2 Protein/genetics, Publisher Correction, Neoadjuvant Therapy, Survival Rate, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Cohort, Female, Adult, medicine.medical_specialty, Disease-Free Survival, Article, 03 medical and health sciences, Germline mutation, Internal medicine, medicine, Chemotherapy, Humans, Pathological, Germ-Line Mutation, BRCA2 Protein, business.industry, lcsh:R, Genetic data, medicine.disease, Confidence interval, 030104 developmental biology, BRCA1 Protein/genetics, lcsh:Q, business

الوصف: BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase sensitivity to DNA-damaging agents. There are conflicting data regarding the prognostic value of BRCA germline mutations in breast cancer (BC) patients. We collected clinical, pathological and genetic data of a cohort 925 BC patients preselected for genetic screening and treated with neoadjuvant or adjuvant chemotherapy, of whom 266 were BRCA carriers. Overall, 171 women carried a BRCA1 mutation, 95 carried a BRCA2 mutation, and 659 were non-carriers. In the entire cohort, there was a prolonged disease-free survival (DFS) for BRCA carriers (hazard ratio (HR) = 0.63; 95% confidence interval (CI), 0.44–0.90 for BRCA1; HR = 0.72; 95%CI, 0.47–1.1 for BRCA2; p = 0.020) and a trend toward prolonged disease-specific survival (DSS; HR = 0.65; 95%CI, 0.40–1.1 for BRCA1; HR = 0.78; 95%CI, 0.44–1.38 for BRCA2; p = 0.19) though not statistically significant. In the TNBC group, BRCA carriers had prolonged DFS (adjusted HR = 0.50; 95%CI, 0.28–0.89 for BRCA1; adjusted HR = 0.37; 95%CI, 0.11–1.25, for BRCA2; p = 0.034) and DSS (adjusted HR = 0.42; 95%CI, 0.21–0.82 for BRCA1; adjusted HR = 0.45; 95%CI, 0.11–1.9 for BRCA2; p = 0.023). In the non-TNBC group, the BRCA1 or BRCA2 mutations did not have any impact on survival. These results suggest that BRCA1/BRCA2 germline mutations are associated with prolonged survival only if women were diagnosed with TNBC.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8acd9b52ca00fe6d903afe15d9d609acTest
http://link.springer.com/article/10.1038/s41598-020-63759-1Test

المؤلفون: Stefan Scherer, Judith Stift, Wu Zhang, Dongyun Yang, Shannon Graver, Peter B. Vermeulen, Stefan Stremitzer, Friedrich Wrba, Heinz-Josef Lenz, Luc Dirix, Mark M. Kockx, Thomas Gruenberger

المصدر: British Journal of Cancer

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Bevacizumab, medicine.medical_treatment, Predictive markers, Gastroenterology, Article, Disease-Free Survival, Resection, Prognostic markers, 03 medical and health sciences, 0302 clinical medicine, Immune system, Internal medicine, medicine, Hepatectomy, Humans, In patient, Rectal cancer, Neoplasm Metastasis, Aged, Cell Proliferation, 030304 developmental biology, Immune phenotype, Aged, 80 and over, 0303 health sciences, Chemotherapy, business.industry, Liver Neoplasms, Perioperative, Middle Aged, Combined Modality Therapy, Neoadjuvant Therapy, Colon cancer, Phenotype, Oncology, Surgical oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, Colorectal Neoplasms, business, Adjuvant, medicine.drug

الوصف: Background Patients with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than those with replacement (non-angiogenic) HGP. This study investigated the association of HGP with the immune phenotype (IP) and clinical outcome after liver resection. Methods CLM of patients treated with perioperative bevacizumab-based chemotherapy and liver resection were investigated. Association of HGP and IP with response, recurrence-free survival (RFS) and overall survival (OS) was investigated. Results One hundred and eighteen patients (M/F 66/52, median age 62.3 (31.0–80.4) years, median follow-up 32.2 (5.0–92.7) months) were enrolled. The inflamed IP was associated with the desmoplastic HGP. The desmoplastic HGP was associated with better radiological and histological response compared to the replacement HGP, respectively. The replacement HGP was associated with shorter RFS (8.7 versus 16.3 months, HR 2.60, P = 0.001) and OS (36.6 months versus not reached, HR 2.32, P = 0.027), respectively. The non-inflamed IP was associated with shorter RFS (10.8 versus 16.5 months, HR 1.85, P = 0.029). The HGP but not the IP remained significant in multivariable analysis for RFS. Conclusions The desmoplastic HGP is associated with the inflamed IP and HGP may be a potential biomarker for adjuvant treatment that includes targeting the immune contexture.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bee036a7a8bb4f0272b46f4110f85da1Test
https://doi.org/10.1038/s41416-020-0812-zTest

المؤلفون: Wolfgang Janni, Julia Jückstock, Maximilian H. Beck, Brigitte Rack, Jens-Uwe Blohmer, Julia Knabl, Paul Jank, Julia Caroline Radosa, MM Karsten, Angela Rademacher

المصدر: Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports

مصطلحات موضوعية: Adult, Vascular Endothelial Growth Factor A, 0301 basic medicine, Oncology, medicine.medical_specialty, Adolescent, Breast surgery, medicine.medical_treatment, lcsh:Medicine, Antineoplastic Agents, Breast Neoplasms, Predictive markers, Article, Cohort Studies, Prognostic markers, Young Adult, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Internal medicine, Humans, Medicine, Young adult, lcsh:Science, Chemotherapy, Multidisciplinary, business.industry, lcsh:R, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Cohort, Female, lcsh:Q, business, Cohort study

الوصف: The antiangiogenic splice variant VEGF-A165b is downregulated in a variety of cancer entities, but little is known so far about circulating plasma levels. The present analysis addresses this question and examines circulating VEGF-A/VEGF-A165b levels in a collective of female high-risk breast cancer patients over the course of treatment. Within the SUCCES-A trial 205 patients were recruited after having received primary breast surgery. Using ELISA VEGF-A/VEGF-A165b concentrations were determined and correlated to clinical characteristics (1) before adjuvant chemotherapy, (2) four weeks and (3) two years after therapy and compared to healthy controls (n = 107). VEGF165b levels were significantly elevated after completion of chemotherapy. Within the breast cancer cohort, VEGF-A165b levels increased two years after completion of chemotherapy. VEGF-A plasma concentrations were significantly elevated in the breast cancer cohort at all examined time points and decreased after treatment. VEGF-A levels two years after chemotherapy correlated with increased cancer related mortality, no such correlation could be found between VEGF-A165b and the examined clinical characteristics. Compared to controls, VEGF-A/VEGF-A165b ratios were decreased in patients before and after chemotherapy. Our data suggests that circulating VEGF-A165b is significantly reduced in women with primary breast cancer at time of diagnosis; furthermore, levels change during adjuvant treatment.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6992865a4860052fb4c057f9c88fb2bTest
http://link.springer.com/article/10.1038/s41598-020-59823-5Test

المؤلفون: Mario M. Dorostkar, Maximilian Niyazi, Jens Blobner, Kai Rejeski, Joerg-Christian Tonn, Robert Forbrig, Niklas Thon, Louisa von Baumgarten, Jorg Dietrich, Philipp Karschnia, Veit M Stoecklein, Jonathan Weller

المصدر: Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports

مصطلحات موضوعية: Male, Oncology, Multivariate analysis, Tumour biomarkers, Prognostic markers, Lateral Ventricles, Multidisciplinary, Brain Neoplasms, Glioma, Middle Aged, Prognosis, Combined Modality Therapy, Isocitrate Dehydrogenase, Neural stem cell, Survival Rate, medicine.anatomical_structure, Chromosomes, Human, Pair 1, Surgical oncology, Medicine, Female, Adult, medicine.medical_specialty, Adolescent, Science, Subventricular zone, Predictive markers, World Health Organization, Article, Young Adult, Internal medicine, Biomarkers, Tumor, medicine, Chemotherapy, Humans, Risk factor, Aged, Retrospective Studies, Radiotherapy, business.industry, Retrospective cohort study, Who grade, medicine.disease, nervous system diseases, CNS cancer, nervous system, Mutation, Dementia, Histopathology, business, Follow-Up Studies

الوصف: Neural stem cells within the subventricular zone were identified as cells of origin driving growth of high-grade gliomas, and anatomical involvement of the subventricular zone has been associated with an inferior clinical outcome. Whether the association between poor outcome and subventricular zone involvement also applies to glioma of lower grades is unclear. We therefore analysed a retrospective cohort of 182 patients with glioma grade 2 (according to the WHO 2016 classification) including 78 individuals (43%) with subventricular zone involvement. Patients with and without subventricular zone involvement did not differ in regard to demographics, histopathology, and molecular markers. Notably, subventricular zone involvement was a negative prognostic marker for malignant progression and overall survival on uni- and multivariate analysis. When patients were stratified according to the cIMPACT-NOW update 6, subventricular zone involvement was negatively associated with outcome in IDH-wildtype astrocytomas and 1p19q-codeleted oligodendrogliomas but not in IDH-mutant astrocytomas. Collectively, subventricular zone involvement may represent a risk factor for worse outcome in glioma WHO grade 2 depending on the molecular tumor signature. The present data confirm the relevance of molecular glioma classifications as proposed by the cIMPACT-NOW update 6. These findings warrant evaluation in prospective cohorts.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a37d4e872ee5f5e960e73387453676dTest
https://doi.org/10.1038/s41598-021-97714-5Test

المؤلفون: Bianca Grosser, Marie Krenauer, Meike Kohlruss, Matthias M. Gaida, Alexander Hapfelmeier, Katja Steiger, Nicole Pfarr, Magdalena Reiche, Julia Slotta-Huspenina, Moritz Jesinghaus, Alexander Novotny, Thomas Schmidt, Wilko Weichert, Lukas Bauer, Katja Ott, Gisela Keller

المصدر: British Journal of Cancer

مصطلحات موضوعية: Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Tumour regression, medicine.medical_treatment, Context (language use), Predictive markers, Article, Prognostic markers, Stomach Neoplasms, Internal medicine, Chromosome instability, Chromosomal Instability, medicine, Humans, ddc:610, neoplasms, Aged, Aged, 80 and over, Chemotherapy, business.industry, Stomach, Cancer, Microsatellite instability, Middle Aged, medicine.disease, female genital diseases and pregnancy complications, Neoadjuvant Therapy, ddc, medicine.anatomical_structure, Surgical oncology, Microsatellite, Female, Gastric cancer, business

الوصف: Background The Cancer Genome Atlas (TCGA) consortium described EBV positivity(+), high microsatellite instability (MSI-H), genomic stability (GS) and chromosomal instability (CIN) as molecular subtypes in gastric carcinomas (GC). We investigated the predictive and prognostic value of these subtypes with emphasis on CIN in the context of neoadjuvant chemotherapy (CTx) in GC. Methods TCGA subgroups were determined for 612 resected adenocarcinomas of the stomach and gastro-oesophageal junction (291 without, 321 with CTx) and 143 biopsies before CTx. EBV and MSI-H were analysed by standard assays. CIN was detected by multiplex PCRs analysing 22 microsatellite markers. Besides the TCGA classification, CIN was divided into four CIN-subgroups: low, moderate, substantial, high. Mutation profiling was performed for 52 tumours by next-generation sequencing. Results EBV(+) (HR, 0.48; 95% CI, 0.23–1.02), MSI-H (HR, 0.56; 95% CI, 0.35–0.89) and GS (HR, 0.72; 95% CI, 0.45–1.13) were associated with increased survival compared to CIN in the resected tumours. Considering the extended CIN-classification, CIN-substantial was a negative prognostic factor in uni- and multivariable analysis in resected tumours with CTx (each p p = 0.026), but was not prognostically relevant. Conclusion A refined CIN classification reveals tumours with different biological characteristics and potential clinical implications.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e719a1fc3a2cda2593613205d984f01fTest
https://pubmed.ncbi.nlm.nih.gov/34671125Test

المؤلفون: Guohua Zhou, Xueping Ma, Shuyun Pang, Hanjun Li, Liying Feng, Shaohua Wang, Shu Xu, Yanan Chu, Bingjie Zou

المصدر: Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)

مصطلحات موضوعية: Adult, Oncology, medicine.medical_specialty, Adjuvant chemotherapy, Science, medicine.medical_treatment, Breast Neoplasms, Article, Prognostic markers, Breast cancer, Late phase, Internal medicine, medicine, Overall survival, Humans, Aged, Cancer, Aged, 80 and over, Chemotherapy, Multidisciplinary, business.industry, Middle Aged, HCT116 Cells, Neoplastic Cells, Circulating, Prognosis, medicine.disease, Peripheral blood, A549 Cells, Chemotherapy, Adjuvant, MCF-7 Cells, Medicine, Female, Breast disease, business

الوصف: To determine the prognostic value of the timing of circulating breast tumour cell measurement during treatment, peripheral blood from 164 patients with breast disease was collected. Circulating tumour cells (CTCs) were enriched by using immunomagnetic nanospheres (IMNs) and were identified by using immunofluorescent staining. The CTC shows nuclear-positive, EpCAM-positive, CK19-positive, and CD45-negative. Patients with CTC positivity (> 19/7.5 mL blood) had shorter progression-free survival (PFS) and overall survival (OS) than those with negative results (≤ 19/7.5 mL blood) at baseline. Surgery caused an increase in the number and prevalence of CTCs, and the effect disappeared on day 14 after surgery. During adjuvant chemotherapy, CTCs detected before therapy was only correlated with PFS; however, CTCs at the end of adjuvant chemotherapy were correlated with both PFS and OS. The PFS and OS of the CTC-positive group were significantly shorter than those of the CTC-negative group at the end-point follow-up visit. The prognostic value of CTCs at different measurement time points was demonstrated during breast cancer treatment. Surgery and chemotherapy affected the prevalence of CTCs, leading to different prognostic relevance of CTCs at different treatment stages. CTCs detected at baseline or in the late phase of treatment are preferable for prognosis.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a43df3c6335db12275a97b00b5617e91Test
https://doi.org/10.1038/s41598-021-92876-8Test

المؤلفون: Elodie Villar, Bénédicte F. Jordan, François Duhoux, Caroline Bouzin, Hélène Dano, Françoise Derouane, Cedric Van Marcke, Florian Gourgue, Patrice D. Cani, Lieven Desmet

المساهمون: UCL - SSS/LDRI - Louvain Drug Research Institute, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie

المصدر: Scientific Reports, Vol. 11, no.1, p. 9922 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
Scientific reports, Vol. 11, no.1, p. 9922 (2021)
Scientific Reports

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, medicine.medical_specialty, Cancer therapy, medicine.medical_treatment, Science, Adipokine, Breast Neoplasms, Logistic regression, Article, Body Mass Index, 03 medical and health sciences, Prognostic markers, 0302 clinical medicine, Breast cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Breast, Obesity, Mastectomy, Aged, Retrospective Studies, Chemotherapy, Multidisciplinary, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Neoadjuvant Therapy, Apelin, 030104 developmental biology, Treatment Outcome, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Cohort, Medicine, Female, business

الوصف: Obesity is a known factor increasing the risk of developing breast cancer and reducing disease free survival. In addition to these well-documented effects, recent studies have shown that obesity is also affecting response to chemotherapy. Among the multiple dysregulations associated with obesity, increased level of the apelin adipokine has been recently shown to be directly involved in the association between obesity and increased breast cancer progression. In this study, we analyzed in a retrospective cohort of 62 breast cancer patients the impact of obesity and tumoral apelin expression on response to neoadjuvant chemotherapy. In the multivariate logistic regression, obesity and high tumoral apelin expression were associated with a reduced response to NAC in our cohort. However, obesity and high tumoral apelin expression were not correlated, suggesting that those two parameters could be independently associated with reduced NAC response. These findings should be confirmed in independent cohorts.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35372ef1914ecbf55b5af41fe3b7fce3Test
https://hdl.handle.net/2078.1/248287Test